Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200-Day Moving Average - Should You Sell?
Spero Therapeutics (NASDAQ:SPRO) shares crossed above the 200-day moving average, trading as high as $2.33. Analysts have mixed ratings: Zacks downgraded to 'hold', Weiss Ratings issued a 'sell', and the consensus target is $5.00. The company reported better-than-expected earnings but has a negative net margin and return on equity. Insider trading and institutional investments are noted, with 25.60% owned by institutions.
Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.16 and traded as high as $2.33. Spero Therapeutics shares last traded at $2.31, with a volume of 170,117 shares trading hands.
Get Spero Therapeutics alerts:
Wall Street Analyst Weigh In
Several research analysts recently weighed in on SPRO shares. Zacks Research downgraded shares of Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, October 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Spero Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Spero Therapeutics currently has an average rating of "Hold" and a consensus price target of $5.00.
Read Our Latest Stock Analysis on SPRO
Spero Therapeutics Stock Performance
The firm has a market capitalization of $130.15 million, a PE ratio of -2.92 and a beta of 1.55. The company has a fifty day moving average price of $2.24 and a 200-day moving average price of $2.16.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. The firm had revenue of $5.44 million during the quarter, compared to analyst estimates of $12.00 million. On average, equities analysts predict that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.
Insider Buying and Selling at Spero Therapeutics
In other news, insider Esther Rajavelu sold 40,270 shares of the business's stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider directly owned 869,450 shares in the company, valued at $2,060,596.50. The trade was a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Spero Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp raised its position in Spero Therapeutics by 11.4% during the first quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock valued at $151,000 after purchasing an additional 21,472 shares during the period. Anson Funds Management LP increased its position in shares of Spero Therapeutics by 98.9% during the 1st quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after purchasing an additional 3,798,932 shares during the last quarter. Capital Asset Advisory Services LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at $94,000. Axxcess Wealth Management LLC bought a new stake in Spero Therapeutics in the second quarter worth $94,000. Finally, XTX Topco Ltd bought a new stake in Spero Therapeutics in the second quarter worth $100,000. 25.60% of the stock is owned by institutional investors.
Spero Therapeutics Company Profile
(Get Free Report)Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Stories
- Five stocks we like better than Spero Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Roth IRA Calculator: Calculate Your Potential Returns
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- Industrial Products Stocks Investing
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Spero Therapeutics Right Now?
Before you consider Spero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.
While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
